D. R. Alessi, S. R. James, C. P. Downes, A. B. Holmes, P. R. Gaffney et al., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B??, Current Biology, vol.7, issue.4, pp.261-269, 1997.
DOI : 10.1016/S0960-9822(06)00122-9

H. Asahina, H. Nokihara, N. Yamamoto, Y. Yamada, Y. Tamura et al., Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study, Investigational New Drugs, vol.30, issue.3, pp.677-684, 2013.
DOI : 10.1007/s10637-012-9860-4

J. M. Askham, F. Platt, P. A. Chambers, H. Snowden, C. F. Taylor et al., AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K, Oncogene, vol.159, issue.1, pp.150-155, 2010.
DOI : 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z

J. S. Aveyard, A. Skilleter, T. Habuchi, and M. A. Knowles, Somatic mutation of PTEN in bladder carcinoma, British Journal of Cancer, vol.80, issue.5/6, pp.904-908, 1999.
DOI : 10.1038/sj.bjc.6690439

L. S. Elting, Clinical model of lifetime cost of treating bladder cancer and associated complications, Urology, vol.68, pp.549-553, 2006.

M. Babjuk, M. Burger, R. Zigeuner, S. F. Shariat, B. W. Van-rhijn et al., EAU guidelines on, Palou Redorta, J., & Roupret, M, 2013.

R. M. Bambury and J. E. Rosenberg, Actionable mutations in muscle-invasive bladder cancer, Current Opinion in Urology, vol.23, issue.5, 2013.
DOI : 10.1097/MOU.0b013e328363a3cd

A. Bamias, I. Tiliakos, M. D. Karali, and M. A. Dimopoulos, Systemic chemotherapy in inoperable or metastatic bladder cancer, Annals of Oncology, vol.17, issue.4, pp.553-561, 2005.
DOI : 10.1093/annonc/mdj079

C. Bartholomeusz and A. M. Gonzalez-angulo, Targeting the PI3K signaling pathway in cancer therapy, Expert Opinion on Therapeutic Targets, vol.56, issue.6, pp.121-130, 2012.
DOI : 10.1158/0008-5472.CAN-04-1399

P. Baumann, S. Mandl-weber, F. Oduncu, and R. Schmidmaier, The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma, Experimental Cell Research, vol.315, issue.3, pp.485-497, 1027.
DOI : 10.1016/j.yexcr.2008.11.007

C. R. Williams, The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro, Urol Oncol, pp.251-00252, 2013.

T. K. Choueiri, Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy, Ann Oncol, vol.24, pp.1466-1472, 2013.

D. Benjamin, M. Colombi, C. Moroni, and M. N. Hall, Rapamycin passes the torch: a new generation of mTOR inhibitors, Nature Reviews Drug Discovery, vol.10, issue.11, pp.868-880, 2011.
DOI : 10.1038/nrd3531

J. S. Bertram and A. W. Craig, Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response, European Journal of Cancer (1965), vol.8, issue.6, 1972.
DOI : 10.1016/0014-2964(72)90137-5

J. A. Pachter, Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin, Mol Cancer Ther, vol.10, pp.1394-1406, 2011.

R. L. Bitting and A. J. Armstrong, Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer, Endocrine Related Cancer, vol.20, issue.3, pp.12-0394, 2013.
DOI : 10.1530/ERC-12-0394

P. C. Black, G. A. Brown, and C. P. Dinney, The impact of variant histology on the outcome of bladder cancer treated with curative intent, Urologic Oncology: Seminars and Original Investigations, vol.27, issue.1, 1014.
DOI : 10.1016/j.urolonc.2007.07.010

A. M. Bogusz, D. R. Brickley, T. Pew, and S. D. Conzen, A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway, FEBS Journal, vol.10, issue.1, pp.2913-2928, 2006.
DOI : 10.1083/jcb.200201053

L. Booth, N. Cruickshanks, T. Ridder, C. S. Chen, S. Grant et al., OSU-03012 interacts with lapatinib to kill brain cancer cells, Cancer Biology & Therapy, vol.15, issue.14, pp.1501-1511, 2012.
DOI : 10.2174/156800911797264743

D. W. Bowles, W. W. Ma, N. Senzer, J. R. Brahmer, A. A. Adjei et al., A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours, British Journal of Cancer, vol.18, issue.5, pp.1085-1092, 2013.
DOI : 10.1186/bcr2883

S. Brachmann, C. Fritsch, S. M. Maira, and C. Garcia-echeverria, PI3K and mTOR inhibitors???a new generation of targeted anticancer agents, Current Opinion in Cell Biology, vol.21, issue.2, 1017.
DOI : 10.1016/j.ceb.2008.12.011

P. M. Lorusso, Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer, Invest New Drugs, p.7, 2014.

M. Burger, J. W. Catto, G. Dalbagni, H. B. Grossman, H. Herr et al., Epidemiology and Risk Factors of Urothelial Bladder Cancer, European Urology, vol.63, issue.2, pp.234-241, 2013.
DOI : 10.1016/j.eururo.2012.07.033

H. Burris, J. Rodon, S. Sharma, R. S. Herbst, J. Tabernero et al., First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors., Journal of Clinical Oncology, vol.28, issue.15_suppl, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.3005

H. A. Burris, Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway, Cancer Chemotherapy and Pharmacology, vol.81, issue.Suppl 3, pp.829-842, 2013.
DOI : 10.1007/s00280-012-2043-3

P. Cairns, E. Evron, K. Okami, N. Halachmi, M. Esteller et al., Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers, Oncogene, vol.16, issue.24, pp.3215-3218, 1998.
DOI : 10.1038/sj.onc.1201855

L. C. Cantley, The Phosphoinositide 3-Kinase Pathway, Science, vol.296, issue.5573, pp.1655-1657, 2002.
DOI : 10.1126/science.296.5573.1655

D. Cappellen, G. Diez-de-medina, S. Chopin, D. Thiery, J. P. Radvanyi et al., Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder, Oncogene, vol.14, issue.25, 1997.
DOI : 10.1038/sj.onc.1201154

J. Altman, J. K. Barr, S. Platanias, and L. C. , Critical roles for mTORC2-and rapamycininsensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells, Proc Natl Acad Sci, vol.107, pp.12469-12474, 2010.

J. S. Carew, K. R. Kelly, and S. T. Nawrocki, Mechanisms of mTOR inhibitor resistance in cancer therapy, Targeted Oncology, vol.24, issue.1, pp.17-27, 2011.
DOI : 10.1007/s11523-011-0167-8

L. C. Cantley, Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit, J Biol Chem, vol.268, pp.9478-9483, 1993.

K. L. Blanchard and J. E. Thomas, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, vol.448, pp.439-444, 2004.

A. Carracedo, J. Baselga, and P. P. Pandolfi, Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors, Cell Cycle, vol.7, issue.24, pp.3805-3809, 2008.
DOI : 10.4161/cc.7.24.7244

N. Chalhoub and S. J. Baker, PTEN and the PI3-Kinase Pathway in Cancer, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.127-50, 2009.
DOI : 10.1146/annurev.pathol.4.110807.092311

F. Chang, J. T. Lee, P. M. Navolanic, L. S. Steelman, J. G. Shelton et al., Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy, Leukemia, vol.17, issue.3, pp.590-603, 2003.
DOI : 10.1038/sj.leu.2402824

G. D. Demetri, Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas, J Clin Oncol, vol.30, pp.78-84, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01058262

C. B. Ching and D. E. Hansel, Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway, Laboratory Investigation, vol.6, issue.10, pp.1406-1414, 2010.
DOI : 10.1016/j.radonc.2006.07.032

J. Cheng, T. Grossman, and H. B. , Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells, Clinical Cancer Research, vol.17, issue.9, pp.2863-2873, 2011.
DOI : 10.1158/1078-0432.CCR-09-3202

K. D. Courtney, R. B. Corcoran, and J. A. Engelman, The PI3K Pathway As Drug Target in Human Cancer, Journal of Clinical Oncology, vol.28, issue.6, pp.1075-1083, 2010.
DOI : 10.1200/JCO.2009.25.3641

P. B. Crino, K. L. Nathanson, and E. P. Henske, The Tuberous Sclerosis Complex, New England Journal of Medicine, vol.355, issue.13, pp.1345-1356, 2006.
DOI : 10.1056/NEJMra055323

H. C. Dan, M. J. Cooper, P. C. Cogswell, J. A. Duncan, J. P. Ting et al., Aktdependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK, 2008.

Z. Darzynkiewicz, H. Zhao, H. D. Halicka, J. Li, Y. S. Lee et al., In search of antiaging modalities: Evaluation of mTOR- and ROS/DNA damage-signaling by cytometry, Cytometry Part A, vol.221, issue.5, 2014.
DOI : 10.1002/cyto.a.22452

J. Maynard, S. A. Ricketts, D. Cross, S. Cosulich, C. C. Chresta et al., Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background, Mol Cancer Ther, vol.11, pp.873-887, 2012.

M. T. Makale and D. L. Durden, An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo, Cancer Chemother Pharmacol, vol.71, pp.867-881, 2013.

K. Du and M. Montminy, CREB Is a Regulatory Target for the Protein Kinase Akt/PKB, Journal of Biological Chemistry, vol.273, issue.49, pp.32377-32379, 1998.
DOI : 10.1074/jbc.273.49.32377

J. L. Rodriguez-peralto, F. De-la-rosa, and J. M. Paramio, PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors, Mol Carcinog, p.22125, 2013.

D. Egan, J. Kim, R. J. Shaw, and K. L. Guan, The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR, Autophagy, vol.7, issue.6, pp.643-644, 2011.
DOI : 10.4161/auto.7.6.15123

J. A. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8, 2009.
DOI : 10.1038/nrc2664

J. A. Engelman, J. Luo, and L. C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nature Reviews Genetics, vol.61, issue.8, pp.606-619, 2006.
DOI : 10.1073/pnas.84.14.5034

H. Fajkovic, J. A. Halpern, E. K. Cha, A. Bahadori, T. F. Chromecki et al., Impact of gender on bladder cancer incidence, staging, and prognosis, World Journal of Urology, vol.185, issue.4, pp.457-463, 2011.
DOI : 10.1007/s00345-011-0709-9

M. Mcdonald and D. M. , Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors, Cancer Res, vol.71, pp.1573-1583, 2011.

N. Fazio, D. Granberg, A. Grossman, S. Saletan, J. Klimovsky et al., Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors, Chest, vol.143, issue.4, pp.955-962, 2013.
DOI : 10.1378/chest.12-1108

G. Fechner, K. Classen, D. Schmidt, S. Hauser, and S. C. Muller, Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer, Urology, vol.73, issue.3, pp.665-668, 2009.
DOI : 10.1016/j.urology.2008.09.070

D. N. Franz, Everolimus for astrocytomas in tuberous sclerosis ??? Author's reply, The Lancet, vol.381, issue.9874, pp.60837-60835, 2013.
DOI : 10.1016/S0140-6736(13)60837-5

M. A. Frias, C. C. Thoreen, J. D. Jaffe, W. Schroder, T. Sculley et al., mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s, Current Biology, vol.16, issue.18, pp.1865-1870, 1817.
DOI : 10.1016/j.cub.2006.08.001

P. Furet, V. Guagnano, R. A. Fairhurst, P. Imbach-weese, I. Bruce et al., Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation, Bioorganic & Medicinal Chemistry Letters, vol.23, issue.13, 2013.
DOI : 10.1016/j.bmcl.2013.05.007

T. M. Dansey, R. D. Hallek, M. O-'brien, and S. M. , Idelalisib and rituximab in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.370, pp.997-1007, 2014.

T. Gao, F. Furnari, and A. C. Newton, PHLPP: a phosphatase that directly dephosphorylates, 2005.

J. M. Garcia-martinez and D. R. Alessi, mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochemical Journal, vol.416, issue.3, 2008.
DOI : 10.1042/BJ20081668

URL : https://hal.archives-ouvertes.fr/hal-00479087

T. Otto, A phase II trial of temsirolimus in second-line metastatic urothelial cancer, Med Oncol, vol.29, pp.2870-2876, 2012.

P. J. Goebell and M. A. Knowles, Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium, Urologic Oncology: Seminars and Original Investigations, vol.28, issue.4, pp.409-428, 2010.
DOI : 10.1016/j.urolonc.2010.04.003

O. Dalesio, B. Biesma, H. J. Smit, A. Termeer, T. J. Hiltermann et al., Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study, J Clin Oncol, vol.29, pp.4320-4326, 2011.

Y. Gui, G. Guo, Y. Huang, X. Hu, A. Tang et al., Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder, Nature Genetics, vol.63, issue.9, pp.875-878, 2011.
DOI : 10.1038/nature07423

Y. Guo, Y. Chekaluk, J. Zhang, J. Du, N. S. Gray et al., involvement in bladder cancer: diverse effects and??therapeutic implications, The Journal of Pathology, vol.2, issue.1, pp.17-27, 2013.
DOI : 10.1002/path.4176

K. Yonezawa, Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action, Cell, vol.110, pp.177-189, 2002.

L. S. Harrington, G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield et al., The TSC1-2 tumor suppressor controls insulin???PI3K signaling via regulation of IRS proteins, The Journal of Cell Biology, vol.65, issue.2, pp.213-223, 2004.
DOI : 10.1038/ncb999

N. Hay, The Akt-mTOR tango and its relevance to cancer, Cancer Cell, vol.8, issue.3, pp.179-183, 2005.
DOI : 10.1016/j.ccr.2005.08.008

T. P. Heffron, M. Berry, G. Castanedo, C. Chang, I. Chuckowree et al., Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor, Bioorganic & Medicinal Chemistry Letters, vol.20, issue.8, pp.2408-2411, 2010.
DOI : 10.1016/j.bmcl.2010.03.046

J. Heitman, N. R. Movva, and M. N. Hall, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, vol.253, issue.5022, pp.905-909, 1991.
DOI : 10.1126/science.1715094

B. Hoang, P. Frost, Y. Shi, E. Belanger, A. Benavides et al., Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor, Blood, vol.116, issue.22, pp.4560-4568, 2010.
DOI : 10.1182/blood-2010-05-285726

H. Z. Huo, Z. Y. Zhou, B. Wang, J. Qin, W. Y. Liu et al., Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014, Biochemical and Biophysical Research Communications, vol.443, issue.2, pp.406-412, 2014.
DOI : 10.1016/j.bbrc.2013.11.099

T. E. Hutson, B. Escudier, E. Esteban, G. A. Bjarnason, H. Y. Lim et al., Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.8, pp.760-767, 2014.
DOI : 10.1200/JCO.2013.50.3961

N. T. Ihle, R. Williams, S. Chow, W. Chew, M. I. Berggren et al., Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling, Mol Cancer Ther, vol.3, pp.763-772, 2004.

K. Inoki, Y. Li, T. Xu, and K. L. Guan, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling, Genes & Development, vol.17, issue.15, pp.1829-1834, 1817.
DOI : 10.1101/gad.1110003

K. Inoki, Y. Li, T. Zhu, J. Wu, and K. L. Guan, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nature Cell Biology, vol.4, issue.9, pp.648-657, 2002.
DOI : 10.1038/ncb839

K. Inoki, T. Zhu, and K. L. Guan, TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival, Cell, vol.115, issue.5, pp.577-590, 2003.
DOI : 10.1016/S0092-8674(03)00929-2

G. Iyer, A. J. Hanrahan, M. I. Milowsky, H. Al-ahmadie, S. N. Scott et al., Genome Sequencing Identifies a Basis for Everolimus Sensitivity, Science, vol.338, issue.6104, p.221, 2012.
DOI : 10.1126/science.1226344

E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg et al., Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nature Cell Biology, vol.59, issue.11, pp.1122-1128, 1123.
DOI : 10.1006/jmbi.2000.4042

G. Jovic, A. W. Ritchie, J. M. Russell, K. Sanders, G. N. Thalmann et al., Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial, Lancet Oncol, vol.13, pp.549-558, 2012.

A. F. Kantor, P. Hartge, R. N. Hoover, J. F. Fraumeni, and . Jr, Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder, Cancer Res, vol.48, pp.3853-3855, 1988.

R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms et al., Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer, Annual Review of Cell and Developmental Biology, vol.17, issue.1, pp.615-675, 2001.
DOI : 10.1146/annurev.cellbio.17.1.615

D. H. Kim, D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek et al., mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery, Cell, vol.110, issue.2, pp.163-175, 2002.
DOI : 10.1016/S0092-8674(02)00808-5

D. H. Kim, D. D. Sarbassov, S. M. Ali, R. R. Latek, K. V. Guntur et al., G??L, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR, Molecular Cell, vol.11, issue.4, pp.895-904, 2003.
DOI : 10.1016/S1097-2765(03)00114-X

J. Kim, M. Kundu, B. Viollet, and K. L. Guan, AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1, Nature Cell Biology, vol.4, issue.2, pp.132-141, 2011.
DOI : 10.1016/j.cub.2010.04.041

J. J. Kim, Recent Advances in Treatment of Advanced Urothelial Carcinoma, Current Urology Reports, vol.18, issue.3, pp.147-152, 2012.
DOI : 10.1007/s11934-012-0238-0

Z. A. Knight, B. Gonzalez, M. E. Feldman, E. R. Zunder, D. D. Goldenberg et al., A Pharmacological Map of the PI3-K Family Defines a Role for p110?? in Insulin Signaling, Cell, vol.125, issue.4, pp.733-747, 2006.
DOI : 10.1016/j.cell.2006.03.035

M. A. Knowles, T. Habuchi, W. Kennedy, and D. Cuthbert-heavens, Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder, Cancer Res, vol.63, pp.7652-7656, 2003.

M. A. Knowles, F. M. Platt, R. L. Ross, and C. D. Hurst, Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer, Cancer and Metastasis Reviews, vol.25, issue.23, pp.305-316, 2009.
DOI : 10.1007/s10555-009-9198-3

P. Korkolopoulou, G. Levidou, E. A. Trigka, N. Prekete, M. Karlou et al., A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma, BJU International, vol.281, issue.11c, p.29, 2012.
DOI : 10.1111/j.1464-410X.2012.11569.x

J. Krawczyk, N. Keane, R. Swords, M. O-'dwyer, C. L. Freeman et al., Perifosine ??? a new option in treatment of acute myeloid leukemia?, Expert Opinion on Investigational Drugs, vol.30, issue.21, pp.1315-1327, 2013.
DOI : 10.1038/nrd2926

D. W. Lamming, L. Ye, D. M. Sabatini, and J. A. Baur, Rapalogs and mTOR inhibitors as anti-aging therapeutics, Journal of Clinical Investigation, vol.123, issue.3, pp.980-989, 2013.
DOI : 10.1172/JCI64099

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582126

J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M. K. Connor et al., PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest, Nature Medicine, vol.9, issue.10, pp.1153-1160, 1116.
DOI : 10.1016/0092-8674(95)90534-0

C. C. Lin, C. H. Hsu, Y. S. Pu, and N. J. Vogelzang, Systemic therapy for metastatic urothelial carcinoma, BJU International, vol.23, issue.7, pp.795-803, 2005.
DOI : 10.1634/theoncologist.10-8-565

J. Lin, D. Sampath, M. A. Nannini, B. B. Lee, M. Degtyarev et al., Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models, Clinical Cancer Research, vol.19, issue.7, pp.1760-1772, 2013.
DOI : 10.1158/1078-0432.CCR-12-3072

D. Lindgren, G. Sjodahl, M. Lauss, J. Staaf, G. Chebil et al., Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma, PLoS ONE, vol.21, issue.6, p.38863, 2012.
DOI : 10.1371/journal.pone.0038863.s008

P. Liu, H. Cheng, T. M. Roberts, and J. J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nature Reviews Drug Discovery, vol.3, issue.8, pp.627-644, 1038.
DOI : 10.1038/nrd2926

Q. Liu, C. Xu, S. Kirubakaran, X. Zhang, W. Hur et al., Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR, Cancer Research, vol.73, issue.8, pp.2574-2586, 2013.
DOI : 10.1158/0008-5472.CAN-12-1702

Q. Li, S. H. Rosenberg, V. L. Giranda, and Y. Luo, Akt Inhibitor A-443654 Interferes with Mitotic Progression by Regulating Aurora A Kinase Expression, Neoplasia, vol.10, issue.8, pp.828-837, 2008.
DOI : 10.1593/neo.08408

E. Lopez-knowles, S. Hernandez, N. Malats, M. Kogevinas, J. Lloreta et al., PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors, Cancer Research, vol.66, issue.15, pp.7401-7404, 2006.
DOI : 10.1158/0008-5472.CAN-06-1182

L. Ma, Z. Chen, H. Erdjument-bromage, P. Tempst, and P. P. Pandolfi, Phosphorylation and Functional Inactivation of TSC2 by Erk, Cell, vol.121, issue.2, pp.179-193, 2005.
DOI : 10.1016/j.cell.2005.02.031

S. M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp et al., Identification and characterization of, 2012.

R. Mallon, I. Hollander, L. Feldberg, J. Lucas, V. Soloveva et al., Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Molecular Cancer Therapeutics, vol.9, issue.4, pp.976-984, 2010.
DOI : 10.1158/1535-7163.MCT-09-0954

M. C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni et al., NVP-BEZ235 as a New Therapeutic Option for Sarcomas, Clinical Cancer Research, vol.16, issue.2, pp.530-540, 2010.
DOI : 10.1158/1078-0432.CCR-09-0816

B. D. Manning and L. C. Cantley, Rheb fills a GAP between TSC and TOR, Trends in Biochemical Sciences, vol.28, issue.11, pp.573-576, 2003.
DOI : 10.1016/j.tibs.2003.09.003

J. J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata et al., Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer, Cancer Biology & Therapy, vol.8, issue.24, 2009.
DOI : 10.4161/cbt.8.24.9987

P. M. Marcus, R. B. Hayes, P. Vineis, M. Garcia-closas, N. E. Caporaso et al., Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction, Cancer Epidemiol Biomarkers Prev, vol.9, pp.461-467, 2000.

P. M. Marcus, P. Vineis, and N. Rothman, NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case???control studies conducted in the general population, Pharmacogenetics, vol.10, issue.2, pp.115-122, 2000.
DOI : 10.1097/00008571-200003000-00003

B. Markman, R. Dienstmann, and J. Tabernero, Targeting the PI3K/Akt/mTOR Pathway ??? Beyond Rapalogs, Oncotarget, vol.1, issue.7, pp.530-543, 2010.
DOI : 10.18632/oncotarget.188

B. Markman, J. Tabernero, I. Krop, G. I. Shapiro, L. Siu et al., Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors, Annals of Oncology, vol.23, issue.9, pp.2399-2408, 2012.
DOI : 10.1093/annonc/mds011

J. Martin, J. Masri, A. Bernath, R. N. Nishimura, and J. Gera, Hsp70 associates with Rictor and is required for mTORC2 formation and activity, Biochemical and Biophysical Research Communications, vol.372, issue.4, pp.578-583, 2008.
DOI : 10.1016/j.bbrc.2008.05.086

A. Radojevic, M. Pljesa-ercegovac, C. Tulic, V. Coric, and T. Simic, GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study, 2013.

J. Basecke, S. Mijatovic, D. Maksimovic-ivanic, M. Milella, A. Tafuri et al., Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance, Oncotarget, vol.3, pp.1068-1111, 2012.

D. Mutations, /. Of-ras, /. Raf, . Mek, P. /. Erk et al., Akt/mTOR cascades which alter therapy response, Oncotarget, vol.3, pp.954-987

M. C. Mendoza, E. E. Er, and J. Blenis, The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation, Trends in Biochemical Sciences, vol.36, issue.6, pp.320-328, 2011.
DOI : 10.1016/j.tibs.2011.03.006

P. Mhawech-fauceglia, R. T. Cheney, and J. Schwaller, Genetic alterations in urothelial bladder carcinoma, Cancer, vol.64, issue.Suppl C, pp.1205-1216, 2006.
DOI : 10.1002/cncr.21743

D. F. Bajorin, Phase II study of everolimus in metastatic urothelial cancer, BJU Int, vol.112, pp.462-470, 2013.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Phase 3 trial of everolimus for metastatic renal cell carcinoma, Cancer, vol.356, issue.suppl, pp.4256-4265, 2010.
DOI : 10.1002/cncr.25219

A. Najafov, E. M. Sommer, J. M. Axten, M. P. Deyoung, and D. R. Alessi, Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1, Biochemical Journal, vol.62, issue.2, pp.357-369, 2011.
DOI : 10.1101/gad.1775409

F. Nazio, F. Strappazzon, M. Antonioli, P. Bielli, V. Cianfanelli et al., mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through??AMBRA1 and TRAF6, Nature Cell Biology, vol.3, issue.4, pp.406-416, 2013.
DOI : 10.1016/S0896-6273(00)81031-4

J. Wu, H. Sawyers, and C. L. , Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci U S A, vol.98, pp.10314-10319, 2001.

T. C. Network, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 2014.

W. J. Oh and E. Jacinto, mTOR complex 2 signaling and functions, Cell Cycle, vol.2, issue.14, pp.2305-2316, 2011.
DOI : 10.1016/j.tibs.2011.03.006

W. J. Oh, C. C. Wu, S. J. Kim, V. Facchinetti, L. A. Julien et al., mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide, The EMBO Journal, vol.15, issue.23, pp.3939-3951, 2010.
DOI : 10.1158/0008-5472.CAN-09-0299

A. Ohtsu, J. A. Ajani, Y. X. Bai, Y. J. Bang, H. C. Chung et al., Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study, Journal of Clinical Oncology, vol.31, issue.31, pp.3935-3943, 2013.
DOI : 10.1200/JCO.2012.48.3552

E. Okajima, T. Hiramatsu, K. Iriya, M. Ijuin, and S. Matsushima, Effect of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine, Urological Research, vol.3, issue.2, 1975.
DOI : 10.1007/BF00256185

O. N. Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer et al., NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature, vol.401, issue.6748, pp.82-85, 1999.
DOI : 10.1038/43466

M. E. Pavel, J. D. Hainsworth, E. Baudin, M. Peeters, D. Horsch et al., Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, The Lancet, vol.378, issue.9808, pp.2005-2012, 2011.
DOI : 10.1016/S0140-6736(11)61742-X

D. M. Sabatini, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, Cell, vol.137, pp.873-886, 1014.

K. G. Pike, K. Malagu, M. G. Hummersone, K. A. Menear, H. M. Duggan et al., Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014, Bioorganic & Medicinal Chemistry Letters, vol.23, issue.5, pp.1212-1216, 2013.
DOI : 10.1016/j.bmcl.2013.01.019

M. Ploeg, K. K. Aben, and L. A. Kiemeney, The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-293, 2009.
DOI : 10.1007/s00345-009-0383-3

L. Ellenson and R. Parsons, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice, Proc Natl Acad Sci U S A, vol.98, pp.10320-10325, 2001.

M. G. Ponzo and M. Park, The Met receptor tyrosine kinase and basal breast cancer, Cell Cycle, vol.9, issue.6, pp.1043-1050, 2010.
DOI : 10.4161/cc.9.6.11033

H. Populo, J. M. Lopes, and P. Soares, The mTOR Signalling Pathway in Human Cancer, International Journal of Molecular Sciences, vol.13, issue.12, 2012.
DOI : 10.3390/ijms13021886

G. Prasad, T. Sottero, X. Yang, S. Mueller, C. D. James et al., Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide, Neuro-Oncology, vol.13, issue.4, pp.384-392, 2011.
DOI : 10.1093/neuonc/noq193

E. Prat, M. Bernues, M. R. Caballin, J. Egozcue, A. Gelabert et al., Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization, Urology, vol.57, issue.5, pp.986-992, 2001.
DOI : 10.1016/S0090-4295(01)00909-8

G. Patel, S. Bernhard, and E. J. , Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity, Cancer Res, vol.68, pp.5915-5923, 2008.

L. S. Pymar, F. M. Platt, J. M. Askham, E. E. Morrison, and M. A. Knowles, Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms, Human Molecular Genetics, vol.17, issue.13, pp.2006-2017, 2007.
DOI : 10.1093/hmg/ddn098

Z. Ahmad, S. Guillard, L. M. Bjerke, L. Kelland, M. Valenti et al., Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases, Cancer Res, vol.67, pp.5840-5850, 2007.

N. Rhodes, D. A. Heerding, D. R. Duckett, D. J. Eberwein, V. B. Knick et al., Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity, Cancer Research, vol.68, issue.7, pp.2366-2374, 1158.
DOI : 10.1158/0008-5472.CAN-07-5783

J. Richter, U. Wagner, P. Schraml, R. Maurer, G. Alund et al., Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer, Cancer Res, vol.59, pp.5687-5691, 1999.

J. Rodon, I. Brana, L. L. Siu, M. J. De-jonge, N. Homji et al., Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, Investigational New Drugs, vol.9, issue.8, p.21, 2014.
DOI : 10.1007/s10637-014-0082-9

J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero, Development of PI3K inhibitors: lessons learned from early clinical trials, Nature Reviews Clinical Oncology, vol.72, issue.3, pp.143-153, 2013.
DOI : 10.1038/nrclinonc.2013.10

R. L. Ross, J. M. Askham, and M. A. Knowles, PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs, Oncogene, vol.9, issue.6, pp.768-776, 2013.
DOI : 10.1002/elps.1150181505

D. M. Sabatini, PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase, Mol Cell, vol.25, pp.903-915, 2007.

D. D. Sarbassov, S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek et al., Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton, Current Biology, vol.14, issue.14, pp.1296-1302, 2004.
DOI : 10.1016/j.cub.2004.06.054

D. D. Sarbassov, D. A. Guertin, S. M. Ali, and D. M. Sabatini, Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex, Science, vol.307, issue.5712, pp.1098-1101, 2005.
DOI : 10.1126/science.1106148

T. Sato, A. Nakashima, L. Guo, and F. Tamanoi, Specific activation of mTORC1 by Rheb Gprotein in vitro involves enhanced recruitment of its substrate protein, J Biol Chem, vol.284, 2009.

E. Seront, A. Pinto, C. Bouzin, L. Bertrand, J. P. Machiels et al., PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation, British Journal of Cancer, vol.62, issue.6, pp.1586-1592, 2013.
DOI : 10.1186/1471-2490-11-19

E. Seront, S. Rottey, B. Sautois, J. Kerger, L. A. D-'hondt et al., Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, Annals of Oncology, vol.23, issue.10, pp.2663-2670, 2012.
DOI : 10.1093/annonc/mds057

V. Sgnaolin, T. C. Pereira, M. R. Bogo, R. Zanin, A. M. Battastini et al., Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: implication of the PI3K?? pathway, Investigational New Drugs, vol.188, issue.4, pp.812-822, 2013.
DOI : 10.1007/s10637-012-9907-6

G. I. Shapiro, J. Rodon, C. Bedell, E. L. Kwak, J. Baselga et al., Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.20, issue.1, pp.233-245, 2014.
DOI : 10.1158/1078-0432.CCR-13-1777

R. J. Shaw and L. C. Cantley, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, vol.12, issue.7092, pp.424-430, 2006.
DOI : 10.1038/nature04869

Y. Shi, J. Gera, L. Hu, J. H. Hsu, R. Bookstein et al., Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779, Cancer Res, vol.62, pp.5027-5034, 2002.

S. Hirohashi, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, Proc Natl Acad Sci U S A, vol.105, 2008.

R. P. Shugg, A. Thomson, N. Tanabe, A. Kashishian, B. H. Steiner et al., Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts: ACTIONS ON CYTOSKELETAL ORGANIZATION, SURVIVAL, AND RESORPTION, Journal of Biological Chemistry, vol.288, issue.49, pp.35346-35357, 2013.
DOI : 10.1074/jbc.M113.507525

R. Simon, H. Burger, A. Semjonow, L. Hertle, H. J. Terpe et al., Patterns of chromosomal imbalances in muscle invasive bladder cancer., International Journal of Oncology, vol.17, pp.1025-1029, 2000.
DOI : 10.3892/ijo.17.5.1025

T. T. Sio, J. Ko, V. K. Gudena, N. Verma, and U. B. Chaudhary, Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review, International Journal of Urology, vol.41, issue.Suppl 1, p.12407, 2014.
DOI : 10.1111/iju.12407

G. Sjodahl, M. Lauss, S. Gudjonsson, F. Liedberg, C. Hallden et al., A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1, PLoS ONE, vol.28, issue.2, p.18583, 2011.
DOI : 10.1371/journal.pone.0018583.s004

A. S. Skopelitou, G. Gloustianou, M. Bai, and K. Huebner, FHIT gene expression in human urinary bladder transitional cell carcinomas, In Vivo, vol.15, pp.169-173, 2001.

J. Gerard, D. Zhuang, S. Zhang, N. Navai, A. Siefker-radtke et al., Frequent truncating mutations of STAG2 in bladder cancer, Nat Genet, vol.45, pp.1428-1430, 2013.

S. L. Abrams, E. W. Wong, K. M. Stadelman, D. M. Terrian, N. R. Leslie et al., Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors, Oncogene, vol.27, pp.4086-4095, 2008.

L. S. Steelman, K. M. Stadelman, W. H. Chappell, S. Horn, J. Basecke et al., Akt as a therapeutic target in cancer, Expert Opinion on Therapeutic Targets, vol.21, issue.9, 2008.
DOI : 10.1074/jbc.M403775200

J. A. Witjes, Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines, Eur Urol, vol.59, pp.1009-1018, 2011.

F. Mccormick and P. T. Hawkins, Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B, Science, vol.277, pp.567-570, 1997.

T. Tamguney, C. Zhang, D. Fiedler, K. Shokat, and D. Stokoe, Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells, Experimental Cell Research, vol.314, issue.11-12, 2008.
DOI : 10.1016/j.yexcr.2008.04.006

D. S. Tan, H. Dumez, D. Olmos, S. K. Sandhu, A. Hoeben et al., First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1, patients with advanced solid tumors and lymphoma, 2010.

H. Tanaka, M. Yoshida, H. Tanimura, T. Fujii, K. Sakata et al., The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations, Clinical Cancer Research, vol.17, issue.10, pp.3272-3281, 2011.
DOI : 10.1158/1078-0432.CCR-10-2882

P. L. Tazzari, A. Cappellini, F. Ricci, C. Evangelisti, V. Papa et al., Multidrug resistance-associated protein 1, 2007.

D. M. Sabatini and N. S. Gray, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1, J Biol Chem, vol.284, 2009.

H. Tigli, D. Seven, M. Tunc, O. Sanli, S. Basaran et al., LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer, Molecular Carcinogenesis, vol.377, issue.8, pp.660-665, 2013.
DOI : 10.1002/mc.21902

I. Coquard, Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study, Target Oncol, vol.8, pp.243-251, 2013.

R. Mallon, I. Hollander, L. Feldberg, J. Lucas, K. Yu et al., PKI- 179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, Bioorg Med Chem Lett, vol.20, pp.5869-5873, 2010.

H. Von-der-maase, L. Sengelov, J. T. Roberts, S. Ricci, L. Dogliotti et al., Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4602-4608, 2005.
DOI : 10.1200/JCO.2005.07.757

D. S. Wang, K. Rieger-christ, J. M. Latini, A. Moinzadeh, J. Stoffel et al., Molecular analysis ofPTEN andMXI1 in primary bladder carcinoma, International Journal of Cancer, vol.45, issue.4, pp.620-625, 2000.
DOI : 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z

N. W. West, A. Garcia-vargas, C. E. Chalfant, and M. A. Park, OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2, BMC Cancer, vol.80, issue.5, pp.1471-2407, 2013.
DOI : 10.1158/0008-5472.CAN-05-3092

M. A. Westhoff, J. A. Kandenwein, S. Karl, S. H. Vellanki, V. Braun et al., The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair, Oncogene, vol.27, issue.40, pp.3586-3596, 2009.
DOI : 10.1038/onc.2009.215

S. V. Williams, C. D. Hurst, and M. A. Knowles, Oncogenic FGFR3 gene fusions in bladder cancer, Human Molecular Genetics, vol.22, issue.4, pp.795-803, 2013.
DOI : 10.1093/hmg/dds486

J. A. Witjes, E. Comperat, N. C. Cowan, M. De-santis, G. Gakis et al., EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines, European Urology, vol.65, issue.4, pp.778-792, 2014.
DOI : 10.1016/j.eururo.2013.11.046

Z. Konstantinovic, R. C. Guimaraes, P. Fumoleau, A. Chan, S. Hachemi et al., Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer, J Clin Oncol, vol.31, pp.195-202, 2013.

R. Robinson, D. R. Chinnaiyan, and A. M. , Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, vol.3, pp.636-647, 2013.

T. Yamori, Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor, J Natl Cancer Inst, vol.98, pp.545-556, 2006.

H. Yang, D. G. Rudge, J. D. Koos, B. Vaidialingam, H. J. Yang et al., mTOR kinase structure, mechanism and regulation, Nature, vol.276, issue.7448, pp.217-223, 2013.
DOI : 10.1107/S0907444909052925

D. S. Yee, N. M. Ishill, W. T. Lowrance, H. W. Herr, and E. B. Elkin, Ethnic Differences in Bladder Cancer Survival, Urology, vol.78, issue.3, pp.544-549, 2011.
DOI : 10.1016/j.urology.2011.02.042

H. You, M. Pellegrini, K. Tsuchihara, K. Yamamoto, G. Hacker et al., FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal, The Journal of Experimental Medicine, vol.203, issue.7, pp.1657-1663, 1626.
DOI : 10.4049/jimmunol.175.6.3790

K. Yu, C. Shi, L. Toral-barza, J. Lucas, B. Shor et al., Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2, Cancer Research, vol.70, issue.2, pp.621-631, 2010.
DOI : 10.1158/0008-5472.CAN-09-2340

R. T. Abraham, P. Nowak, and A. Zask, Biochemical, cellular, and in vivo activity of novel ATPcompetitive and selective inhibitors of the mammalian target of rapamycin, Cancer Res, vol.69, 2009.

H. Cheng, J. G. Christensen, J. L. Kan, and S. Bagrodia, PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity, Mol Cancer Ther, vol.10, pp.2189-2199, 2011.

Z. Zeng, D. Sarbassov-dos, I. J. Samudio, K. W. Yee, M. F. Munsell et al., Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, vol.109, issue.8, pp.3509-3512, 2006.
DOI : 10.1182/blood-2006-06-030833

H. Zhou and S. Huang, Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis, 2011.
DOI : 10.2174/9781681082332116030009

C. S. Chen, From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3- phosphoinositide-dependent protein kinase-1 inhibitors, Cancer Res, vol.64, pp.4309-4318, 2004.

R. Zoncu, A. Efeyan, and D. M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing, Nature Reviews Molecular Cell Biology, vol.20, issue.1, pp.21-35, 2011.
DOI : 10.1038/nrm3025

Z. Q. Zou, L. N. Zhang, F. Wang, J. Bellenger, Y. Z. Shen et al., The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells, Mol Med Rep, vol.5, pp.503-508, 2011.